Related Experiment Videos
Connatal Pelizaeus-Merzbacher disease
C A Haenggeli1, E Engel, G P Pizzolato
1Department of Paediatrics, Hôpital Cantonal Universitaire, Geneva, Switzerland.
Abstract:
Type II connatal Pelizaeus-Merzbacher disease is a degenerative disease of the developing nervous system. Confirmation of diagnosis is only by histopathological examination at present. The authors describe an infant with several clinical features which are apparently unique to this disease. These features may allow a presumptive clinical diagnosis to be made in other cases, thereby allowing valuable genetic counselling to be given before the death of the affected infant enables confirmation by autopsy.
Insights
Pelizaeus-Merzbacher disease type II is a rare nervous system disorder. Unique clinical features in an infant may enable early presumptive diagnosis and genetic counseling before autopsy confirmation.
Area of Science:
- Neurology
- Genetics
- Developmental Biology
Background:
- Pelizaeus-Merzbacher disease (PMD) is a rare, X-linked recessive congenital disorder.
- It is characterized by progressive demyelination in the central nervous system.
- Currently, definitive diagnosis relies on histopathological examination post-mortem.
Observation:
- The study presents a case of Type II connatal Pelizaeus-Merzbacher disease.
- The infant exhibited a constellation of clinical signs and symptoms.
- These features appear to be distinct and potentially unique to this specific subtype of PMD.
Findings:
- The identified clinical features may serve as early indicators for Type II PMD.
- This could facilitate a presumptive clinical diagnosis in affected infants.
- Histopathological confirmation remains the gold standard but is post-mortem.
Implications:
- Early presumptive diagnosis can significantly impact patient management.
- It allows for timely and crucial genetic counseling for families.
- This approach offers the potential to provide support before the infant's prognosis is confirmed by autopsy.